摘要
目的观察肝动脉化疗栓塞联合经脾动脉间接性门静脉内灌注化疗药物治疗原发性肝癌的疗效,并探讨其与血清TNF-α、sIL-2R以及VEGF水平改变的关系。方法45例行肝动脉化疗栓塞联合经脾动脉间接性门静脉内灌注化疗药物,观察术后血清TNF-α、sIL-2R以及VEGF水平的改变及其预后。结果治疗后血清TNF-α、sIL-2R以及VEGF水平均低于治疗前(P<0.01);生存期2年以上者与2年以内者之间存在差异;双灌注治疗后1、2、3、4年的生存率分别为71.1%、51.1%、24.4%、8.9%。结论双灌注介入治疗后血清TNF-α、sIL-2R以及VEGF水平的变化与预后相关。
Objective To study the therapeutic efficacy of transcatheter arterial chemoembolization combined with lienalis infusion in primary hepatocellular carcinoma （HCC） and its relation with the serum levels of TNF-α,sIL-2R and VEGF.Methods A total of 45 patients were included in a transcatheter arterial chemoembolization combined with lienalis infusion therapy to portal vein indirectly.The serum levels of TNF-α,sIL-2R and VEGF and the disease prognosis were analyzed.Results The post-treatment serum level of TNF-α,sIL-2R and VEGF in HCC patients were lower than the pre-treatment level（P0.01）.There was no significant difference in prognosis between patients who had been treated for 2 years and more than two years.The survival rates for 1,2,3 and 4 years of treatment were 71.1%,51.1%,24.4% and 8.9%,respectively.Conclusion Double intra-arterial infusion of anti-cancerous agents reduce the serum levels of serum TNF-α,sIL-2R and VEGF in HCC patients and improves prognosis.
出处
《临床肝胆病杂志》
CAS
2010年第2期203-204,209,共3页
Journal of Clinical Hepatology
关键词
原发性肝癌
双灌注介入
TNF-Α
SIL-2R
VEGF
primary liver cancer
double intra-arterial infusion of anti-cancerous agents
TNF-α
sIL-2R
VEGF
